The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

Tue, 10th Nov 2020 17:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Wheaton Precious Metals Corp - precious metals streaming company - Third quarter revenue jumps 37% to USD307.3 million and net earnings almost double to USD149.9 million from USD76.0 million. Declares USD0.12 per share fourth quarter payout, 20% increase. Quarterly gold production down 11% annually to 91,770 ounces, silver down 0.2% to 6,028, palladium down 0.5% to 5,444 ounces and gold equivalent down 6.6% to 171,370 ounces. Company began life on Main Market in late October.

----------

Power Metal Resources PLC - metals exploration and development company - Updates on Red Rock Australasia Pty Ltd joint-venture, as does partner Red Rock Resources PLC. Power Metal has just shy of a 50% stake, Red Rock holds just over 50%. Joint venture notified that it has had seven further license applications accepted. "RRAL will now advertise the seven applications in newspapers with statewide and local circulation, and after a three week exposure period, the Department of Jobs, Precincts & Regions of the State of Victoria will begin the application assessment process," Power Metal adds. Separately, Power Metal explains drilling has begun at Silver Peak silver project, Canada.

----------

Kavango Resources PLC - Botswana-focused exploration firm - Plans to raise GBP2.0 million through issue of 72.7 million shares at 2.75 pence each.

----------

Bluejay Mining PLC - exploration firm with assets in Finland and Greenland - Enters into pact with Rio Tinto PLC at Enonkoski nickel project which could see Rio take 75% stake in asset by completing USD20.0 million worth of expenditure. Bluejay explains it will pay GBP100,000 in shares to Magnus Minerals Ltd to settle historical royalty claims.

----------

Orosur Mining Inc - Toronto-based mineral exploration firm focused on Columbia and Uruguay - Receives USD582,170 from Minera Monte Aguila SAS, a joint-venture between Newmont Corp and Agnico Eagle Mines Ltd as part of Anza project, Colombia earn-in. "The company has commenced field activities at the Anza project. Work programs remain subject to the changing status of the Covid-19 pandemic in the local region, however thus far this has been managed without incident," Orosur says.

----------

Panthera Resources PLC - gold exploration and development company with assets in West Africa and India - Says partner Moydow Holdings Ltd arranges USD1 million equity financing to go towards work programmes in West Africa.

----------

Nostra Terra Oil & Gas Co PLC - AIM-listed company focused on the prolific Permian Basin in West Texas - Says Cypress farm-out well at Pine Mills oil field has now spudded. "We continue to be pleased with the progress made by our partner. The result of this well can have a significant impact for the company in terms of cashflow as well as an increase in reserves, also leading the way to additional development in Pine Mills," Chief Executive Officer Matt Lofgran says.

----------

Union Jack Oil PLC and Egdon Resources PLC - oil and gas producers and partners at North Kelsey, Lincolnshire - Reports "positive progress" at Biscathorpe project on Lincolnshire licence PEDL253. Joint-venture identifies potential drilling targets which can be accessed through a side-track on existing Biscathorpe-2 well. "Egdon, on behalf of the PEDL253 joint venture partners, will be submitting an application for planning permission for the side-track drilling operation, associated testing and in a success case the long-term production of oil at the site," the companies said.

----------

Plexus Holdings PLC - AIM-listed oil and gas engineering services firm - Enters into licence agreement with Cameron International Ltd to supply the POS-GRIP wellhead friction grip product and HG metal-to-metal seal method. Cameron will pay Plexus royalty based on number of wellheads sold in range of 3% and 6% until 2029. "In addition to royalty fees, Cameron shall pay the company a capital licence fee payment of USD500,000 in exchange for the non-exclusive licence rights," Plexus says.

----------

Dekel Agri-Vision PLC - West Africa-focused agriculture company - Says crude palm oil sales volumes improve 40% year-on-year to 1,843 tonnes. Average sales price per tonne up 28% to EUR636. Output up 19% to 1,818 tonnes.

----------

ProPhotonix Ltd - manufacturer of LED illumination systems - Announces launch of COBRA Clean FX1, a UVC LED based lamp providing disinfection. "UVC is a proven method in the disinfection of water, air, and surfaces which has shown to be effective against pathogens such as E. coli, L. innocua, and Covid-19," ProPhotonix says.

----------

Water Intelligence PLC - environmental services and technology company - Begins sales of Orca sewer diagnostic product. Completes reacquisition of American Leak Detection franchisee in Brisbane, Australia.

----------

Equals Group PLC - London-based payments and e-banking firm - Begins B2B relationship with HomeSend, a cross-border payments firm. "Under this agreement, the group will bolster HomeSend activities in the UK, further enabling customers to send money to UK bank accounts in real time and with upfront transparency of all associated fees," Equals says.

----------

Prime People PLC - London-based recruiter - Plans buyback of up to GBP250,000 worth of shares.

----------

Checkit PLC - Cambridge-based workflow management firm - Revenue in nine months ended October 31 improves to GBP9.8 million from GBP6.6 million year-on-year. "The business performed ahead of the board's expectations during Q3," Checkit says. Third-quarter revenue flat annually at GBP3.4 million.

----------

Ethernity Networks Ltd - network processing technology supplier - Secures order from North American "tier 1" aerospace contractor customer to provide ENET Avionic Ethernet Switch firmware and software.

----------

SEEEN PLC - London-based social media technology firm - Says third quarter revenue up 23% annually at USD2.7 million, year-to-date revenue down 9% at USD6.4 million. Third quarter audience views up 77% to 4.9 billion.

----------

Telit Communications PLC - internet of things and machine to machine communications company - Says revenue in nine months to September 30 down 11% annually to USD245 million from USD274.5 million, "remaining resilient compared to H1 despite continued lockdown measure".

----------

Immupharma PLC - pharmaceutical company - Says US Food & Drug Administration offers to accept type A meeting request for optimised international phase 3 trial of Lupuzor in systemic lupus erythematosus, an auto-immune disease. Immupharma says partner Avion Pharmaceuticals submitted full dossier on November 6. In normal circumstances, this "leads to a guidance meeting within 30 days", Immupharma says. "However, FDA timeframes cannot be guaranteed."

----------

ValiRx PLC - clinical-stage biotechnology company - Enters into agreement with Kalos Therapeutics, a US biotechnology firm, to evaluate peptide KTH222 as drug candidate to treat ovarian cancer sufferers. "Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel," ValiRx says.

----------

NetScientific PLC - life sciences investor - Portfolio company PDS Biotechnology Corp says VERSATILE-002 phase 2 clinical trial evaluating PDS0101 with Merck & Co's Keytruda for treatment of head and neck cancer is now open.

----------

Dunedin Enterprise Investment Trust PLC - investment company focused on UK mid-market companies - Says tender offer oversubscribed. Says 13.7 million shares validly tendered. Notes that following scale back exercise, 2.5 million shares purchased at roughly GBP9.8 million in total.

----------

Urban Logistics REIT PLC - London-based logistics-focused real estate investment trust - Acquires logistics site in Hertfordshire for GBP34.3 million. "The 12-acre site comprises five units, three of which are let to Muller UK & Ireland Group, a major producer and distributor of dairy products, until 2030 with a rent review in 2025. The passing rent is GBP8.75 per square foot," Urban Logistics says.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.